The burden of inhibitors in haemophilia patients
| Autor: | S. Grancha, Christopher E. Walsh, Víctor Jiménez-Yuste, Guenter Auerswald |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Burden of disease
medicine.medical_specialty Factor VIII business.industry Hematology Health Care Costs 030204 cardiovascular system & hematology Haemophilia medicine.disease Hemophilia A Poor quality 03 medical and health sciences 0302 clinical medicine Clinical evidence Immunology von Willebrand Factor medicine Immune Tolerance Quality of Life Animals Humans Cost of care Intensive care medicine business 030215 immunology |
| Zdroj: | Thrombosis and haemostasis. 116 |
| ISSN: | 2567-689X |
| Popis: | SummaryThe burden of disease in haemophilia patients has wide ranging implications for the family and to society. There is evidence that having a current inhibitor increases the risk of morbidity and mortality. Morbidity is increased by the inability to treat adequately and its consequent disabilities, which then equates to a poor quality of life compared with non-inhibitor patients. The societal cost of care, or `burden of inhibitors’, increases with the ongoing presence of an inhibitor. Therefore, it is clear that successful eradication of inhibitors by immune tolerance induction (ITI) is the single most important milestone one can achieve in an inhibitor patient. The type of factor VIII (FVIII) product used in ITI regimens varies worldwide. Despite ongoing debate, there is in vitro and retrospective clinical evidence to support the use of plasma-derived VWF-containing FVIII concentrates in ITI regimens in order to achieve early and high inhibitor eradication success rates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|